Intas
Manufacturing · India · 46,656 Employees
View Company Info for Free
About
Headquarters
Sola Bridge S.g. Hwy, Thaltej, Ahmedabad, Gujar...Phone Number
+91 2717660100Website
www.intaspharma.comRevenue
$12.7 BillionIndustry
Most Recent Scoops
Highlights
$106.3M
Total Funding Amount
$106.3M
Most Recent Funding Amount
2
Number of Funding Rounds
Who is Intas
Intas Org Chart
Is Intas your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Intas recently announced quarterly report
Click to see if Intas had a recent Job posting/layoffs
Check if Intas has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Intas is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Intas
Product Launch: Get notified when Intas launches new products
Intas, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Intas has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Intas Email Formats
Intas uses at least 5 email formats with first_last (ex. John_Smith@intaspharma.com) being used 64.4% of the time
Intas Email Formats | Percentage | |
---|---|---|
first_last | John_Smith@intaspharma.com | 64.4% |
first initials + last | JSmith@intaspharma.com | 6.9% |
first.last | John.Smith@intaspharma.com | |
first + last | JohnSmith@intaspharma.com | |
first | John@intaspharma.com |
Get Verified Emails
Intas financials insights
Gather financial insights about Intas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Intas Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Intas Tech Stack
A closer look at the technologies used by Intas
Most Recent Scoops
Intas News & Media
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth
Agreement demonstrates the expanding leadership of Accord BioPharma and Intas in the biosimilar market RALEIGH, N.C., Dec. 3, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development of...Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
- Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor -FDA Approves IMULDOSA® (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
With the approval of IMULDOSA, Accord BioPharma's biosimilar portfolio continues to grow while expanding treatment options appropriate for patients RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ -- Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on...Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer
- HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC - HETRONIFLY® (serplulimab) is expected to become the first anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC AHMEDABAD, India,...
Frequently Asked Questions Regarding Intas
Intas was founded in 1976. This company provides the manufacturing and research of pharmaceuticals. Their headquarters are located in Ahmedabad, Gujarat, India.... Read More